To include your compound in the COVID-19 Resource Center, submit it here.

Reata reports Phase II data for omaveloxolone in mitochondrial myopathies

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported top-line data from the Phase II MOTOR trial in 53 patients with mitochondrial myopathies showing that omaveloxolone (oral RTA 408) missed the primary endpoint of improving peak workload

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers